Related Experiment Video

Updated: Jul 7, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B

Tsui-Chin Huang1, Hsin-Yi Chang, Chun-Hua Hsu

  • 1Institute of Molecular and Cellular Biology, National Taiwan University, Taipei 106, Taiwan.

Journal of Proteome Research
|February 16, 2008
PubMed

Insights

This study identified ATP synthase as a target in breast cancer. The inhibitor Aurovertin B effectively reduced cancer cell proliferation by inducing apoptosis and cell cycle arrest.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Targeting tumor-specific proteins enhances anticancer treatment efficacy.
  • Identifying novel protein targets is crucial for effective cancer therapy.

Purpose of the Study:

  • To investigate tumor-specific protein expression in human breast carcinoma.
  • To evaluate the potential of ATP synthase as a therapeutic target in breast cancer.

Main Methods:

  • Proteomic analysis of human breast carcinoma tissues.
  • Treatment of breast cancer cell lines with ATP synthase inhibitors, specifically Aurovertin B.
  • Assessment of cell proliferation, apoptosis, and cell cycle phase distribution.

Main Results:

  • ATP synthase was found to be upregulated in breast carcinoma tissues and located on the plasma membrane of cancer cells.
  • Aurovertin B demonstrated significant inhibition of breast cancer cell proliferation with minimal impact on normal cells.
  • Aurovertin B induced apoptosis and G0/G1 cell cycle arrest in breast cancer cells.

Conclusions:

  • ATP synthase is a promising therapeutic target for breast cancer.
  • Aurovertin B exhibits potent antitumorigenic properties and warrants further investigation for cancer chemotherapy.
  • Targeting ATP synthase offers a selective approach for breast cancer treatment.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...